Figure 4
From: Recombinant Human Prion Protein Inhibits Prion Propagation in vitro
Inhibition of human PrPSc amplification by truncated recombinant human PrP and different anti-PrP antibodies.
(A) PMCA was performed with the mixture of human PrPSc (seeds) from iCJDVV2 and brain homogenates from TgWV (substrates) in the presence of rHuPrP23-231 (Hu23), rHuPrP90-231 (Hu90), rHuPrP23-145 (Hu145), or different antibodies against PrP (0.1 μM each), respectively. The four antibodies include SAF32 against human PrP59-89, 3F4 against PrP105-112, 6H4 against PrP145-152 and 8H4 against PrP175-185. The result is a representative of three independent experiments. (B) Inhibition of PrPSc amplification was quantified using densitometric analysis based on three independent experiments. Of all recombinant PrP species and anti-PrP antibodies examined, recombinant human PrP23-231 exhibited the highest inhibition compared to others (**: p < 0.01; ***: p < 0.001). (C) PMCA was performed with the mixture of human PrPSc (seeds) from iCJDVV2 and brain homogenates from TgWV (substrates) in the presence of Hu23, Hu90, g5p, MCT, OCD4, or 3F4 (0.1 μM each), respectively. The Western blot shown is a representative of three independent experiments. (D) Inhibition of PrPSc amplification was quantified using densitometric analysis based on three independent experiments. In addition to rHuPrP23-231 and rHuPrP90-231, g5p and MCT also significantly inhibited PrPSc amplification (**: p < 0.01; ***: p < 0.001), whereas OCD4 and 3F4 did not (p > 0.05).
